Life Science Leader - Home Page
WEBVolastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow. OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in ...
Companies To Watch: Aurion Biotech - Life Science Leader
WEBAug 30, 2024 · By Ben Comer, Chief Editor, Life Science Leader. Greg Kunst. Developing an allogeneic cell therapy for eye diseases at scale for the masses . Snapshot. Privately-held Aurion Biotech is developing an allogeneic combination cell therapy — neltependocel, which is allogeneic human corneal endothelial cells, combined with Y-27632, an inhibitor of Rho-associated, coiled-coil containing protein ...
Driving Innovation In Life Sciences With Agile
WEBSep 1, 2016 · Implementing the Agile approach can help life sciences organizations innovate to meet these challenges while also reducing costs. In short, companies can see a step-change in their innovation capabilities by adopting and extending Agile beyond IT, moving to an Agile culture, embracing the benefits …
Exploring Functional Uses Of AI In Life Sciences
WEBMar 19, 2024 · The future of AI in the life sciences industry has transformative potential in many different sectors. AI will significantly speed up the creation of personalized treatments and drug discovery, shortening the journey from research to clinical use. Advancements in AI will lead to more accurate medical diagnostics and extend healthcare services ...
FSP Or Full-Service Outsourcing For Clinical Trials? - Life Science …
WEBDec 3, 2013 · Functional service provider (FSP) partnerships have been gaining traction in recent years because of their potential to increase efficiency and flexibility in outsourcing without compromising quality. Well-defined services within the scope of a clinical trial project or program (e.g. data management, biostatistics, or medical writing) are good ...
Is The API In Capsule Method Overshadowing The Science Of …
WEBJan 30, 2010 · The fact is, API in capsule/bottle approaches for early clinical studies may defer, but will not eliminate, the need to conduct formulation development and process optimization. It is therefore critical to weigh carefully the impact on the overall development plan (as well as cost and time) of using neat drug substance-filled capsules/vials ...
CMO Leadership Awards - Life Science Leader
WEBA Strategic Tool For Companies Who Outsource. To support the vetting process for selecting outsourcing partners, Outsourced Pharma and Life Science Leader developed the CMO Leadership Awards in 2011. Winning CMOs are chosen through impartial market research based on feedback from sponsor companies that utilize outsourcing services.
3 Essentials For A Fit-For-Purpose Compliance Strategy In …
WEBApr 1, 2022 · 3 Essentials For A Fit-For-Purpose Compliance Strategy In Decentralized Pharma. By Penelope Przekop, MSQA , RQA P-GCP, and Valerie Przekop. Outsourcing and technology have morphed our industry into a new decentralized model. Now, each sponsor must carefully develop an ongoing compliance strategy considering its unique business model and its ...
How Serial Entrepreneur Robert Hariri Is Revolutionizing Cell …
WEBAug 1, 2019 · Advice From A Successful Serial Entrepreneur. Robert Hariri, M.D., Ph.D., a successful serial entrepreneur and CEO of Celularity, believes a lot of companies fail because they have a very linear development strategy. And if they reach a milestone and fail, there isn’t much of a future. “A lot of scientists have a discovery — a molecule, a ...
Life Science Connect Podcast
WEBOn today’s episode of the Life Science Connect podcast, Clinical Leader Chief Editor Ed Miseta talks about a virtual conference on patient centricity called “Focus On Patients,” covering the successes and challenges of putting patients at the center of clinical trials. 001: The JPM Conference. In this episode, Life Science Leader magazine ...